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ABSTRACT
Background: Hepatocellular carcinoma (HCC) is the 3rd leading cause of 
cancer-related death worldwide. The majority of HCCs are diagnosed in a stage 
that is not eligible for curative resection. For intermediate stage HCC, transarterial 
chemoembolization (TACE) is the recommended treatment. We evaluated the safety 
and efficacy of DSM (degradable starch microspheres) as embolic agent in transarterial 
chemoembolization (TACE) for the treatment of intermediate stage, non-resectable 
hepatocellular carcinoma (HCC).
Methods and Findings: A national, multi-center observational study on the safety 
and efficacy of DSM-TACE for the treatment of intermediate HCC was conducted. The 
recruitment period for the study was from January 2010 to June 2014. The primary 
endpoints were safety and treatment response according to the mRECIST criteria.
A total of 179 DSM-TACE procedures in 50 patients were included in the analysis. 
The therapeutic efficacy assessed with mRECIST was as follows: complete response 
(n=1; 2 %), 21 partial response (42 %), 13 stable disease (26 %), 9 progressive 
disease (18 %), and 6 incomplete data (12 %). Thus, the objective response rate was 
44% (n=22) and disease control rate was 70% (n=35).
A total of 76 immediate adverse events (AE) and 2 severe adverse events 
(SAE) were recorded. Forty-eight percent of patients (n=24) did not encounter any 
immediate AE/SAE. Between treatments, a total of 66 AE and one SAE were recorded. 
Twenty-four patients (48 %) did not encounter any AE/SAE in between treatments.
Conclusion: The use of DSM as a TACE embolic agent appears to be safe for the 
treatment of HCC and has promising efficacy.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the 5th most 
common cancer and 3rd leading cause of cancer-related 
death worldwide [1]. The majority of HCCs are diagnosed 
in a stage that is not eligible for curative resection, i.e., 
intermediate or advanced stage HCC. For intermediate 
stage HCC, transarterial chemoembolization (TACE) is 
the recommended treatment [2]. A survival benefit has 
been demonstrated for TACE-treated HCC over the best 
supportive care [3] alone.
Different embolic agents are available for use 
in the TACE procedure. TACE using Lipiodol is the 
most common technique for the treatment of HCC [4]. 
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The use of drug eluting beads (DEB) offers another 
safe and efficient treatment option, even in advanced 
HCC [5–7]. Conventional Lipiodol-TACE has two 
major drawbacks: (1) it has ill-defined and prolonged 
vascular occlusion over a half-time from 5 to 12 weeks 
[4] and (2) has lipophilic characteristics, while the most 
used chemotherapeutic agents, e.g., doxorubicin, are 
hydrophilic. The embolic agent DEB shows a well-
calculable binding and release of chemotherapeutics, but 
causes a permanent vascular occlusion [7]. The duration 
of the occlusion is of importance since the dependent 
release of vascular endothelial growth factor (VEGF) 
can promote metastatic seeding. Degradable starch 
microspheres (DSM), such as EmboCept (PharmaCept 
GmbH, Berlin, Germany), combine a well-defined 
transient vascular occlusion and optimized binding 
capacities for chemotherapeutic agents [8, 9]. This study 
presents results on the clinical efficacy, toxicity, and 
safety of DSM-TACE using EmboCept microspheres 
for the treatment of intermediate stage HCC.
RESULTS
Fifty patients were included between January 2010 
and March 2015. They received a total of 179 DSM-
TACE procedures. The youngest patient was 44 years old 
upon inclusion in the study, and the oldest patient was 83 
years old (mean ± SD = 67.7 ± 10 years; Table 1). HCC 
was surgically pre-treated in 4 patients (8.0 %) before 
chemoembolization, and one patient (2.0 %) underwent 
radiofrequency-ablation (RFA). HCC metastases were 
not surgically pre-treated in any patients. Systemic 
chemotherapy preceded DSM-TACE in 2 patients (4.0 %).
On inclusion, 28 patients had less than 4 HCC 
lesions (56.0 %) and 17 patients had 4 or more lesions 
(34.0 %, no data = 5). These lesions were in the left lobe 
in 4 patients (8.0 %), in the right lobe in 20 patients (40.0 
%), and in both lobes in 17 patients (34.0 %; no data = 
9). Infiltrative tumor growth was observed in 11 patients 
(11.0 %), a nodular growth pattern in 36 patients (72.0 %) 
and an infiltrative as well as nodular growth pattern in 3 
patients (6.0 %).
DSM-TACE
DSM-TACE was used in a palliative treatment 
setting in 41 out of 50 cases (82.0 %). In five cases 
(10.0 %), chemoembolization was initially intended as a 
curative treatment. In two cases (4.0 %), it was applied 
before patients were listed for liver transplantation (no 
data = 1).
Application of DSM-TACE was conducted 
selectively via A. hepatica propria in 7 procedures 
(3.9 %), A. hepatica dextra in 48 procedures (26.8 %), 
both A. hepatica dextra and sinistra in 25 procedures 
(14.0 %), A. hepatica sinistra in 15 procedures (8.4 %), 
superselective catheterization in 45 procedures (25.1 
%), both superselective catheter placement and selective 
catheterization of the A. hepatica dextra in 15 procedures 
(8.4 %) and A. hepatica dextra, A. hepatica sinistra and 
superselective catheterization in 21 procedures (11.7 %, 
no data = 3; Table 2).
A mean of 353.6 ± 140.1 mg of DSM was used 
per treatment, and 66.1 ± 60.1 ml of contrast agent 
was added. Application of chemotherapeutic agents 
spanned over 22.9 ± 17.6 minutes. DSM was given 
mixed with chemotherapeutic agents in 172 procedures, 
following chemotherapeutic agents in 1 case and prior to 
chemotherapeutic agents in 3 cases (no data = 3).
Doxorubicin, Epirubicin, and Carboplatin were 
used as the sole chemotherapeutic agent in 174 cases 
(Table 3, no data = 5). Doxorubicin was used in 84 
cases with dosages from 25 to 50 mg (50 mg n = 70), 
Epirubicin in 87 cases with dosages from 20 to 100 mg, 
and Carboplatin in 3 cases with either 300 mg (n = 2) or 
450 mg (n = 1).
Safety
In 2 patients, treatment had to be discontinued 
because of an allergic reaction to DSM during the first 
chemoembolization. Within 24 hours of DSM-TACE in 
45 treatments (25.2 %), epigastric pain was registered as 
an immediate AE. Nausea and vomiting occurred after 20 
treatments (11.2 %). After 2 treatments (1.1 %), dyspnea 
occurred, while after 1 treatment (0.6 %), shivering 
occurred. After 7 treatments (3.9 %), elevated temperature 
was reported. All adverse events were attributable to 26 of 
50 patients. Thus, 24 patients (48.0 %) did not encounter 
any adverse events, 24 (48.0 %) had minor adverse events 
(AE), and 2 (4.0 %) had severe adverse events (SAE).
Between DSM-TACE treatments, epigastric pain 
was registered in 27 cases and nausea and vomiting 
in 26 cases. After 7 procedures, elevated temperature 
was reported. In 2 cases, diarrhea occurred. One 
patient developed a gastric ulcer. Two treatments were 
followed by transient neutropenia and one by transient 
thrombopenia. These adverse events were attributable to 
26 of 50 patients. In summary, AE occurred in 25 out of 
50 patients (50.0 %), and one patient (2.0 %) had a SAE 
(Figure 1).
Efficacy and tumor response
Using the mRECIST criteria for the therapeutic 
efficacy assessment, the results were as follows: CR = 2 
% (n=1), PR = 42 % (n=21), SD = 26 % (n=13), and PD = 
18 % (n=9); for 12 % of patients (n=6), the follow up data 
were incomplete (Table 4). Thus, the objective response 
(OR) was 44 % (n=22) and disease control (DC) was 70 
% (n=35; Figure 2).
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DISCUSSION
HCC is the 3rd most common cause of cancer-
related death worldwide [1]. Patients and medical 
professionals often face the challenge of the disease no 
longer being eligible for curative resection at the time 
of diagnosis. TACE has proven to be a safe and efficient 
therapeutic option in treating intermediate stage HCC 
[2]. It can be both a stand-alone treatment or bridge to 
other therapies, including resection or transplantation, 
if sufficient reduction of tumor burden can be realized. 
TACE comprises a vast field of setups with respect to 
its two major components: the chemotherapeutic agent 
and embolic agent. The latter is of major importance for 
the TACE procedure. The embolic agent delivers the 
chemotherapeutic agent to the target tissue and causes 
Table 2: Details on the TACE procedures
Catheter position
 A. hepatica propria (AHP) 7/179 (3.9%)
 A. hepatica dextra (AHD) 48/179 (26.8 %)
 A. hepatica sinistra (AHS) 15/179 (8.4 %)
 AHD + AHS 25/179 (14.0 %)
 AHD + AHD + superselective 21/179 (11.7 %)
 AHD + superselective 15/179 (8.4 %)
 superselective; no data 45/179 (25.1 %); 3/179 (1.7%)
DSM dose (mg) 353.6 ± 140.1
Contrast agent (ml) 66.1 ± 60.1
Injection time of CTX (min) 22.9 ± 17.6
TACE sequence
 CTX and DSM combined 172/179 (96.1 %)
 CTX prior to DSM 1/179 (0.6 %)
 DSM prior to CTX; no data 3/179 (1.7 %); 3/179 (1.7 %)
Table 1: Baseline characteristics of patients, pre-treatment, and disease extent
Age (mean ± SD; min; max) 67.7 ± 10; 44; 83 years
Pre-treatment
 Surgery 4/50 (8.0 %)
 RFA 1/50 (2.0 %)
 Chemotherapy 2/50 (4.0 %)
Disease extent
 < 4 hepatic metastases 28/50 (56.0 %)
 ≥ 4 hepatic metastases 17/50 (34.0 %)
 no. of metastases unknown 5/50 (10.0 %)
 left lobe 4/50 (8.0 %)
 right lobe 20/50 (40.0 %)
 bilobar; no data 17/50 (34.0 %); 9/50 (18.0 %)
 infiltrative growth 11/50 (22.0 %)
 nodular growth 36/50 (72.0 %)
 infiltrative & nodular g. 3/50 (6.0 %)
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a vascular occlusion, which is a key component in 
TACE treatment. First, reduced blood flow extends the 
exposure time to CTX [7]. Second, the reduced wash 
out ramps up the locoregional concentration of CTX [7]. 
Third, ischemia can cause tumor necrosis [13]. Ischemia 
also causes changes to the cellular signaling pathways, 
possibly facilitating CTX uptake [14]. Finally, ischemia 
may facilitate the cytotoxic action of CTX by creating 
an oxygen-deprived environment that is favorable 
for free-radical formation [15]. DSM microspheres 
represent a major class of degradable embolic agents 
besides conventional Lipiodol and permanent occlusive 
drug eluting beads. Conventional TACE using Lipiodol 
has two major disadvantages. First, the lipophilic 
property reduce its capacity for loading with most 
chemotherapeutic agents, which are predominantly 
hydrophilic [16]. Additionally, it has been shown to be 
associated with a remarkable systemic VEGF (vascular 
endothelial growth factor) response, which may facilitate 
tumor growth and metastatic seeding [17, 18], which is 
Table 3: Details on the chemotherapeutic agents used
Chemotherapeutic agent Dosage (mg) n
Doxorubicin 25 10
34, 5 1
40 3
50 70
Epirubicin 20 1
25 1
30 4
50 52
55 5
60 21
100 2
no data 1
Carboplatin 300 2
450 1
Figure 1: Number of patients affected by adverse (AE) and severe adverse events (SAE). Immediate events (< 24 h from 
DSM-TACE) and delayed events (> 24 from DSM-TACE).
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possibly due to occlusion of the smallest caliber vessels, 
causing a characteristic ischemia-reperfusion (I/R) 
timeframe [14, 19]. Both DSM and DEB do not elicit this 
type of dominant VEGF response. Most microspheres 
and beads are 50 microns or larger, sparing the smallest 
vessels. With respect to the characterization of I/R, one 
must consider the unique anatomic properties of the liver 
with the dual blood supply, which is dominated by the 
portal vein (approx. 80%) and complemented by the 
hepatic artery (approx. 20%). Furthermore, this demands 
a clear and strict separation from the observation 
and evaluation of primary liver cancers, such as HCC 
with a hypervascular architecture, and secondary liver 
malignancies, such as colorectal metastasis. With respect 
to the combined results (metastases and HCC) published 
by Sun et al. for HepaSphere microspheres (Merit 
Medical Systems Inc., South Jordan, UT, USA) [20], our 
results showed a promising objective response rate of 44 
%, and disease control rate of 70 %, which is worthy 
of further evaluation in randomized clinical trials. The 
safety and toxicity profile of Embocept DSM-TACE was 
very favorable in our cohort, which was composed of 179 
DSM-TACE procedures in 50 patients with intermediate 
stage, non-resectable HCC. Kirchhoff et al. reported 
partial remission in 36 % of patients and no complete 
remission using degradable starch microspheres and 
Lipiodol [21]. In 2014, Malagari et al. reported an 
objective response rate of 68.9 % using DSM-TACE 
[16]. Largely, the results of TACE-treatment in liver 
malignancies vary widely. This is due, but not limited, 
to non-standardized TACE procedures and applications, 
different embolic agents, different chemotherapeutic 
agents, different pre-treatments, varying treatment 
concepts (stand-alone TACE vs. bridging), small cohort 
sizes, predominant single-center studies, different 
tumor entities and tumor burden. Further, multi-center 
randomized clinical trials must be performed to compare 
strict, standardized TACE-procedures to gain further 
insight into which embolic/chemotherapeutic agent 
combination is best for the treatment of HCC.
Table 4: Final tumor response grading using mRECIST
mRECIST
complete remission 1 (2 %)
partial remission 21 (42 %)
stable disease 13 (26 %)
progress 9 (18 %)
no data 6 (12 %)
objective response 22 (44 %)
disease control 35 (70 %)
Figure 2: Tumor response of HCC to DSM-TACE. CR = complete response, PR = partial response, SD = stable disease, PD = progressive 
disease.
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To specifically gain insights on EmboCept as 
an embolization agent in DSM-TACE, our study had 
the following limitations: it was set up as a solely 
observational study with non-standardized DSM-TACE 
procedures, including injection and combination of 
chemotherapeutics, non-strict inclusion and exclusion 
criteria in a multicenter design, as well as a loose 
imaging protocol. This study consequently lacked data 
and dedicated analyses on clinical outcome parameters, 
such as the local control rate, progression free survival, 
and overall survival. For a solely observational study, we 
accepted these limitations in favor of making promising 
results on the safety and efficacy of DSM-TACE as an 
available treatment option.
In conclusion, from the data presented here, 
EmboCept DSM-TACE seems to be a safe treatment 
option in intermediate stage HCC, and the results 
regarding its efficacy are promising. Nonetheless, further 
studies with strict protocols and long-term follow-ups 
comparing cTACE or DEB-TACE are required.
MATERIALS AND METHODS
Patients
Patients older than 18 years with confirmed 
HCC of intermediate stage that was not suitable for 
resection or any other curative treatment strategy were 
eligible for inclusion in this study. Both, nodular and 
infiltrative growth, as well as single-lobar and bilobar 
disease, were suitable for inclusion. Patients with prior 
chemoembolization, enrollment in any other clinical 
trial and/or other contraindications against DSM-TACE, 
such as lacking safe arterial access to the intrahepatic 
malignancy, were precluded from participation in the 
study.
Informed consent and approval by the local ethics 
committee were waived because the study was solely 
observational, and the study was conducted in accordance 
with the Declaration of Helsinki, the International 
Conference on Harmonization Guideline on Good 
Clinical Practice, and national laws and regulations where 
applicable.
Study design
This was a national, multi-center observational 
study on the safety and efficacy of DSM-TACE for the 
treatment of intermediate HCC. The recruitment period for 
the study was from January 2010 to June 2014.
DSM-TACE
EmboCept S DSM 35/50 is a short-term embolizate 
that is composed of degradable starch microspheres with 
an average diameter of 50 micrometers. The microspheres 
are enzymatically degraded by serum alpha-amylases in 
the blood, yielding a half-life of approximately 35-50 
minutes, both in vivo and in vitro. The resulting glucose 
fragments are further degraded by the reticulocyte 
system. A specific side-effect of the transient vascular 
occlusion strategies, such as in TACE, is the back-flow 
of the embolizate to non-target regions, causing ischemia 
and severe pain. DSM ameliorates the risk of profound 
organ damages due to its self-limiting degradation. With 
degradable starch microspheres, partial resumption 
of blood flow is observed after approximately 10 to 15 
minutes [10].
After inclusion and imaging (MRI and/or CT), 
patients received DSM-TACE. Six weeks later, patients 
were restaged and received another cycle of DSM-TACE 
when suitable.
A catheter for DSM-TACE was placed via the 
femoral artery in all patients. Selective (A. hepatica 
propria, A. hepatica sinistra, A. hepatica dextra) or super-
selective catheterization was subject to discretion by 
the interventionalist in charge depending on the tumor 
burden, vascular status, and individual patient and case 
characteristics.
The preparation and dosage of DSM was in line 
with the manufacturer’s instructions. The choice of 
chemotherapeutic agent or a combination of up to three 
drugs was used depending on the individual patient and 
case characteristics. DSM allows for the use of different 
types of co-administered contrast agents. As in all TACE 
procedures, the order of application of the embolizate and 
chemotherapeutic agent was as follows: the embolizate 
was applied first, followed by the chemotherapeutic(s) or 
both in parallel.
Imaging
Within this observational study, the imaging 
modality for the staging of the intrahepatic lesions was 
chosen according to institution and/or interventionalist 
preference. Before and after DSM-TACE, all patients 
underwent CT or MR imaging using a multiphase liver 
imaging protocol. All patients underwent the same 
imaging modalities throughout their participation in the 
study to enable a reliable rating according to mRECIST.
Safety
A key point of the observational study reported here 
was to evaluate the DSM-TACE treatment-emergent side 
effects. The side effects were separately registered within 
24 hours of the TACE-procedure (immediate). The side 
effects between single treatment sessions (delayed) were 
based on the CTCAE (Common Terminology Criteria for 
Adverse Events) V4.0 classification of acute and subacute 
toxic side effects, covering both serious adverse events 
(SAE) and adverse events (AE).
Efficacy
The efficacy of DSM-TACE in HCC treatment was 
rated according to mRECIST for the assessment of tumor 
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necrosis in locoregional therapies [11, 12]. Complete 
response (CR) was defined as the disappearance of any 
intratumoral arterial enhancement in all target lesions. 
Partial response (PR) was defined as at least a 30% 
decrease in the sum of the diameters of viable (contrast 
enhancing) target lesions. Progressive disease (PD) was 
defined as an increase of at least 20% in the sum of the 
diameters of the viable (enhancing) target lesions, and 
stable disease included all cases that did not qualify 
as a either partial response or progressive disease. As 
previously reported [5], disease control (DC) was defined 
and calculated as CR + PR + SD. Objective response (OR) 
was defined and calculated as CR + PR.
Statistical analysis
For statistical calculations, analysis, and plotting, we 
used GraphPad Prism version 5.00a for Mac (GraphPad 
Software, San Diego California, U.S.A.). Statistically 
significant differences were assumed at p <0.05.
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